The IASLC Lung Cancer Staging Project: A Proposal for a New International Lymph Node Map in the Forthcoming Seventh Edition of the TNM Classification for Lung Cancer

Abstract

The accurate assessment of lymph node involvement is an important part of the management of lung cancer. Lymph node "maps" have been used to describe the location of nodal metastases. However, discrepancies in nomenclature among maps used by Asian and Western countries hinder analyses of lung cancer treatment outcome. To achieve uniformity and to promote future analyses of a planned prospective international database, the International Association for the Study of Lung Cancer proposes a new lymph node map which reconciles differences among currently used maps, and provides precise anatomic definitions for all lymph node stations. A method of grouping lymph node stations together into "zones" is also proposed for the purposes of future survival analyses.

Impact of lymph node management on resectable non-small cell lung cancer patients

“…CT-brain and bone scans were performed if clinically relevant. These patients represent all clinical early stage NSCLC who underwent curative intent-complete pulmonary resection with SLND or sampling of the hilum and mediastinum according to the international LN map for TNM classification of lung cancer (16). Exclusion criteria were patients who received any induction therapy (radiation or chemotherapy).…”

Ultrasonografía bronquial con aspiración por aguja fina en el estudio lesiones adyacentes a la vía aérea central

“…Se registraron variables demográficas tales como edad y género, características de la lesión descritas de acuerdo a TAC de tórax clasificán-dolas según su ubicación utilizando el mapa mediastínico IASLC 9 , morfología (redonda, oval, triangular, otra), márgenes (definidos o irregular), tamaño de la lesión y complicaciones asociadas al procedimiento. El diagnóstico anatomopatológi-co de las muestras fue realizado en el servicio de Anatomía Patológica mediante un operador ciego a la historia clínica y resultado diagnóstico del procedimiento previo.…”

Dual-time-point FDG PET/CT: Is It Useful for Lymph Node Staging in Patients with Non-Small-Cell Lung Cancer?

“…Histopathological tumor types were adenocarcinoma in 33, squamous cell carcinoma in 31, large cell carcinoma in 1, and poorly differentiated NSCLC in 4. LN staging of all patients was done according to the 7th edition of the TNM staging system for lung cancer, which was published by the International Union Against Cancer and the American Joint Committee on Cancer [12].…”